FDA blames Israel-based Teva for Adderall shortage

Teva says it expects ADHD drug's inventory recovery in the coming months, as some people may encounter a backorder based on timing and high demand

The U.S. Food and Drug Administration (FDA) said on Wednesday there was a shortage of Adderall, a treatment for attention deficit hyperactivity disorder, following intermittent manufacturing delays at Israel-based Teva pharmaceutical firm.
  • Follow Ynetnews on Facebook and Twitter

  • U.S.-listed shares of Teva Pharmaceutical Industries Ltd were down 1.5% at $7.95 in trading after the bell.
    2 View gallery
    מטה ה-FDA
    מטה ה-FDA
    FDA headquarters
    (Photo: EPA)
    Adderall is an FDA-approved prescription drug made of two stimulants amphetamine and dextroamphetamine.
    Other manufacturers continue to produce amphetamine mixed salts, but there is not sufficient supply to continue to meet U.S. market demand through those producers, the U.S. health regulator said.
    According to the FDA's website, supply recovery for different doses and forms of the drug ranges from October 2022 to March 2023.
    2 View gallery
    (Photo: Reuters)
    "It is possible that some people may encounter a backorder (intermittently) based on timing and high demand, but these are only temporary ... and we expect inventory recovery in the coming months," Teva said on Wednesday.
    The company will continue to have challenges supplying Adderall for the next two to three months, Bloomberg News reported last week.
    The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.